ストックスクリーナーアプリを入手
2.31
10.81%
-0.28
プレマーケット:
2.32
0.010
+0.43%
前日終値:
$2.59
開ける：
$2.6
24時間の取引高:
98,569
Relative Volume:
1.66
時価総額：
$77.16M
収益：
-
当期純損益:
$-34.26M
株価収益率:
-0.1222
EPS:
-18.9056
ネットキャッシュフロー:
$-15.62M
1週間 パフォーマンス:
-22.22%
1か月 パフォーマンス:
-19.51%
6か月 パフォーマンス:
-54.79%
1年 パフォーマンス:
-61.82%
1日の値動き範囲:
$2.258
$2.6998
1週間の範囲:
$2.258
$3.10
52週間の値動き範囲:
$2.258
$9.50
Dogwood Therapeutics Inc Stock (DWTX) Company Profile
名前
Dogwood Therapeutics Inc
セクター
電話
(866) 620-8655
住所
44 MILTON AVENUE, ALPHARETTA
Compare DWTX vs VRTX, REGN, ALNY, ARGX, INSM
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
DWTX
Dogwood Therapeutics Inc
|
2.31 | 86.51M | 0 | -34.26M | -15.62M | -18.91 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 115.58B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 79.23B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 43.59B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 43.26B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 31.97B | 606.42M | -1.28B | -997.58M | -6.403 |
Dogwood Therapeutics Inc (DWTX) 最新ニュース
DWTX: 143 Patients Enrolled in Phase 2b Trial of Halneuron Results Expected in 3Q26 - Research Tree
DWTX: 143 Patients Enrolled in Phase 2b Trial of Halneuron®; Results Expected in 3Q26 - Yahoo Finance
US Market Recap: What is the long term forecast for Dogwood Therapeutics Inc stockWeekly Profit Recap & Free Fast Entry Momentum Trade Alerts - baoquankhu1.vn
Dogwood Therapeutics (DWTX) to Release Quarterly Earnings on Monday - Defense World
HC Wainwright Issues Positive Forecast for DWTX Earnings - MarketBeat
If You Invested $1,000 in Dogwood Therapeutics (DWTX) - Stock Titan
History Review: Will Dogwood Therapeutics Inc benefit from government policyTrade Performance Summary & Low Risk High Win Rate Picks - baoquankhu1.vn
Aug Decliners: Will Dogwood Therapeutics Inc benefit from government policyPortfolio Profit Report & Daily Chart Pattern Signals - baoquankhu1.vn
What is HC Wainwright’s Estimate for DWTX FY2030 Earnings? - Defense World
What is HC Wainwright's Estimate for DWTX FY2030 Earnings? - MarketBeat
Performance Recap: Is Dogwood Therapeutics Inc stock showing strong momentum - baoquankhu1.vn
Dogwood Therapeutics 2025 Annual Report – Pipeline, Clinical Progress, Intellectual Property, and Risks in Neuropathic Pain Drug Development - Minichart
Dogwood Therapeutics (DWTX) Q4 Loss Narrows to $0.26, Beats Estimates - AlphaStreet
Moving Averages: Is Dogwood Therapeutics Inc stock showing strong momentum2026 Short Interest & Risk Adjusted Buy and Sell Alerts - baoquankhu1.vn
Dogwood Therapeutics (DWTX) details Halneuron pain program and going-concern risk - Stock Titan
Dogwood Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results - Bitget
DWTX: Halneuron® Phase 2b trial advances, with funding secured through key 2026 milestones - TradingView
Dogwood Therapeutics (Nasdaq: DWTX) ramps R&D and extends cash runway - Stock Titan
Dogwood Therapeutics Q4 net loss narrows on lower expenses - TradingView
Dogwood Therapeutics extends cash runway as pain drug trial advances - Stock Titan
Short Interest in Dogwood Therapeutics, Inc (NASDAQ:DWTX) Decreases By 15.1% - MarketBeat
Dogwood Therapeutics (NASDAQ:DWTX) Shares Up 1.7%Time to Buy? - MarketBeat
Dogwood Therapeutics Shareholders Approve Warrant Exercise Proposal - The Globe and Mail
Dogwood Therapeutics, Inc. 8-K SEC Filing March 11, 2026: Company Information, Stock, and Key Details - Minichart
Dogwood Therapeutics (Nasdaq: DWTX) holders back major warrant exercise - Stock Titan
CK Life Sciences Establishes Sequencio Therapeutics to Advance Therapeutic Cancer Vaccines Development - The Manila Times
Sentiment Watch: What is the long term forecast for Dogwood Therapeutics Inc stockTrend Reversal & Accurate Buy Signal Alerts - baoquankhu1.vn
Maxim Group Sticks to Its Buy Rating for Dogwood Therapeutics (DWTX) - The Globe and Mail
Dogwood Therapeutics (DWTX) CMO receives grant of 82,500 stock options - Stock Titan
DWTX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Bull Run: Does Dogwood Therapeutics Inc stock benefit from AI growthJuly 2025 Gainers & Reliable Entry Point Trade Alerts - baoquankhu1.vn
Shorts Report: Is Dogwood Therapeutics Inc stock showing strong momentumDollar Strength & Real-Time Stock Movement Alerts - baoquankhu1.vn
Aug Update: Does Dogwood Therapeutics Inc stock benefit from AI growthWeekly Stock Summary & Reliable Breakout Forecasts - baoquankhu1.vn
DWTXDogwood Therapeutics Latest Stock News & Market Updates - Stock Titan
Dogwood Therapeutics (NASDAQ:DWTX) Earns Buy Rating from HC Wainwright - Defense World
Analysts Offer Insights on Healthcare Companies: Corcept Therapeutics (CORT), Praxis Precision Medicines (PRAX) and Dogwood Therapeutics (DWTX) - The Globe and Mail
Is Dogwood Therapeutics Inc. stock showing strong momentumMarket Volume Report & Growth Oriented Trading Recommendations - mfd.ru
What’s the MACD signal for Dogwood Therapeutics Inc.Trade Entry Summary & Reliable Entry Point Trade Alerts - mfd.ru
Market Wrap: How cyclical is Dogwood Therapeutics Incs revenue streamDividend Hike & Free Safe Capital Growth Stock Tips - baoquankhu1.vn
Pullback Watch: Whats the MACD signal for Dogwood Therapeutics Inc2025 Key Highlights & Expert Approved Momentum Ideas - baoquankhu1.vn
What’s the analyst consensus on Dogwood Therapeutics Inc.July 2025 Gainers & Reliable Price Action Trade Plans - mfd.ru
Will Dogwood Therapeutics Inc. stock benefit from AI adoption2025 Winners & Losers & Weekly Top Performers Watchlists - mfd.ru
Will Dogwood Therapeutics Inc. benefit from geopolitical trendsEarnings Recap Report & Risk Managed Investment Strategies - mfd.ru
Warrant approval could dilute Dogwood Therapeutics (NASDAQ: DWTX) holders - Stock Titan
How is Dogwood Therapeutics Inc. managing supply chain issuesQuarterly Portfolio Review & Low Risk Entry Point Guides - mfd.ru
What is the PEG ratio of Dogwood Therapeutics Inc.Weekly Profit Analysis & Accurate Buy Signal Notifications - mfd.ru
Why Dogwood Therapeutics Inc. stock could benefit from AI revolutionJuly 2025 Snapshot & Technical Confirmation Trade Alerts - mfd.ru
DWTX: Financing Secures Funding Through Phase 2b Data Readout - Smartkarma
Institution Moves: Will Dogwood Therapeutics Inc. benefit from geopolitical trends2025 Macro Impact & Precise Swing Trade Entry Alerts - baoquankhu1.vn
Dogwood Therapeutics Announces 50% Enrollment in Ongoing Halneuron® Phase 2b Trial, Top Line Results Anticipated in Q3 2026 - markets.businessinsider.com
Cancer pain drug Halneuron shows early promise as major trial hits halfway - Stock Titan
Dogwood Therapeutics Inc (DWTX) 財務データ
収益
当期純利益
現金流量
EPS
1.82%
大文字化:
|
ボリューム (24 時間):